Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celiac Disease: Novel therapeutic and diagnostic approaches.

Description du projet

Nouveaux outils moléculaires pour étudier la maladie cœliaque

La maladie cœliaque est une affection auto-immune déclenchée par le gluten présent dans le blé, l’orge et le seigle. Compte tenu de la forte prévalence de la maladie en Europe, il est nécessaire de mettre en place des traitements ciblés allant au-delà d’un régime sans gluten et d’améliorer les outils de diagnostic. Financé par le programme Actions Marie Skłodowska-Curie, le projet GLUCHIRAL étudiera comment les peptides immunogènes du gluten (PIG) traversent l’intestin grêle. Les chercheurs ont pour objectif de développer des inhibiteurs peptidiques contre les PIG afin de bloquer leurs effets nocifs et de mettre au point de nouveaux traitements. En même temps, le projet sensibilisera à la maladie cœliaque et aux pathologies associées au gluten.

Objectif

Celiac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically predisposed individuals, affecting a substantial portion of the European population (1.4%). A significant number of CD cases remain undiagnosed (75%), leading to untreated disease and its associated symptoms. These range from immediate gastrointestinal and extra-intestinal distress to long-term complications such as osteoporosis, infertility, and cancer, among others, placing substantial strain on society and healthcare systems. As the primary treatment for CD remains a strict gluten-free diet, there is a pressing need for innovative approaches to alleviate the burden of inadvertent gluten exposure. This proposal aims to investigate the molecular mechanisms governing the transport of gluten immunogenic peptides (GIP) across the small intestine and to develop a chiral-based strategy for the design of enantiomeric peptides that can inhibit GIP toxicity and immunogenicity. Our objectives are: 1) To develop a focused library of enantiomeric peptide inhibitors of GIP that could be used as novel therapeutic agents for CD. 2) To elucidate the molecular mechanisms of GIP transport and immunogenicity across the small intestine using GIP enantiomers as probes. 3) To establish a liquid chromatography–mass spectrometry (LC-MS) assay for GIP quantitation in biological samples as a novel diagnostic tool for assessing gut permeability in CD patients. The successful accomplishment of these objectives will provide valuable insights into GIP activity and transport within intestinal epithelium and immune cells. Moreover, it offers the potential to identify novel peptide-based therapeutics against GIP, with the possibility of further commercialization. Lastly, the success of this proposal carries the critical importance of raising awareness about CD and pathologies associated with gluten consumption, addressing the alarming rate of undiagnosed cases within the European population.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-MSCA-2023-PF-01

Voir tous les projets financés au titre de cet appel

Coordinateur

UNIVERSIDAD DE SEVILLA
Contribution nette de l'UE
€ 226 441,20
Coût total
Aucune donnée

Partenaires (1)